Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Silke Gillessen; A. Omlin; G. Attard; J. S. de Bono; E. Efstathiou; K. Fizazi; S. Halabi; P. S. Nelson; O. Sartor; M. R. Smith; H. R. Soule; H. Akaza; T. M. Beer; H. Beltran; A. M. Chinnaiyan; G. Daugaard; I. D. Davis; M. De Santis; C. G. Drake; R. A. Eeles; S. Fanti; M. E. Gleave; A. Heidenreich; M. Hussain; N. D. James; F. E. Lecouvet; C. J. Logothetis; K. Mastris; S. Nilsson; W. K. Oh; D. Olmos; A. R. Padhani; C. Parker; M. A. Rubin; J. A. Schalken; H. I. Scher; A. Sella; N. D. Shore; E. J. Small; C. N. Sternberg; H. Suzuki; C. J. Sweeney; I. F. Tannock; B. Tombal

doi:10.1093/annonc/mdv257

Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Silke Gillessen, A. Omlin, G. Attard, J. S. de Bono, E. Efstathiou, K. Fizazi, S. Halabi, P. S. Nelson, O. Sartor, M. R. Smith, H. R. Soule, H. Akaza, T. M. Beer, H. Beltran, A. M. Chinnaiyan, G. Daugaard, I. D. Davis, M. De Santis, C. G. Drake, R. A. EelesS. Fanti, M. E. Gleave, A. Heidenreich, M. Hussain, N. D. James, F. E. Lecouvet, C. J. Logothetis, K. Mastris, S. Nilsson, W. K. Oh, D. Olmos, A. R. Padhani, C. Parker, M. A. Rubin, J. A. Schalken, H. I. Scher, A. Sella, N. D. Shore, E. J. Small, C. N. Sternberg, H. Suzuki, C. J. Sweeney, I. F. Tannock, B. Tombal

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

268 Citations (Scopus)

Résumé

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

langue originale	Anglais
Pages (de - à)	1589-1604
Nombre de pages	16
journal	Annals of Oncology
Volume	26
Numéro de publication	8
Les DOIs	https://doi.org/10.1093/annonc/mdv257
état	Publié - 1 août 2015

Accès au document

10.1093/annonc/mdv257

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., ... Tombal, B. (2015). Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 26(8), 1589-1604. https://doi.org/10.1093/annonc/mdv257

@article{5d2a71ae5f2b4efe8caaa94bc77274e2,

title = "Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015",

abstract = "The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-na{\"i}ve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.",

keywords = "Advanced prostate cancer, Castration-na{\"i}ve prostate cancer, Castration-resistant prostate cancer, Consensus, Therapeutics",

author = "Silke Gillessen and A. Omlin and G. Attard and {de Bono}, {J. S.} and E. Efstathiou and K. Fizazi and S. Halabi and Nelson, {P. S.} and O. Sartor and Smith, {M. R.} and Soule, {H. R.} and H. Akaza and Beer, {T. M.} and H. Beltran and Chinnaiyan, {A. M.} and G. Daugaard and Davis, {I. D.} and {De Santis}, M. and Drake, {C. G.} and Eeles, {R. A.} and S. Fanti and Gleave, {M. E.} and A. Heidenreich and M. Hussain and James, {N. D.} and Lecouvet, {F. E.} and Logothetis, {C. J.} and K. Mastris and S. Nilsson and Oh, {W. K.} and D. Olmos and Padhani, {A. R.} and C. Parker and Rubin, {M. A.} and Schalken, {J. A.} and Scher, {H. I.} and A. Sella and Shore, {N. D.} and Small, {E. J.} and Sternberg, {C. N.} and H. Suzuki and Sweeney, {C. J.} and Tannock, {I. F.} and B. Tombal",

year = "2015",

month = aug,

day = "1",

doi = "10.1093/annonc/mdv257",

language = "English",

volume = "26",

pages = "1589--1604",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "8",

}

Gillessen, S, Omlin, A, Attard, G, de Bono, JS, Efstathiou, E, Fizazi, K, Halabi, S, Nelson, PS, Sartor, O, Smith, MR, Soule, HR, Akaza, H, Beer, TM, Beltran, H, Chinnaiyan, AM, Daugaard, G, Davis, ID, De Santis, M, Drake, CG, Eeles, RA, Fanti, S, Gleave, ME, Heidenreich, A, Hussain, M, James, ND, Lecouvet, FE, Logothetis, CJ, Mastris, K, Nilsson, S, Oh, WK, Olmos, D, Padhani, AR, Parker, C, Rubin, MA, Schalken, JA, Scher, HI, Sella, A, Shore, ND, Small, EJ, Sternberg, CN, Suzuki, H, Sweeney, CJ, Tannock, IF & Tombal, B 2015, 'Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015', Annals of Oncology, VOL. 26, Numéro 8, p. 1589-1604. https://doi.org/10.1093/annonc/mdv257

TY - JOUR

T1 - Management of patients with advanced prostate cancer

T2 - Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

AU - Gillessen, Silke

AU - Omlin, A.

AU - Attard, G.

AU - de Bono, J. S.

AU - Efstathiou, E.

AU - Fizazi, K.

AU - Halabi, S.

AU - Nelson, P. S.

AU - Sartor, O.

AU - Smith, M. R.

AU - Soule, H. R.

AU - Akaza, H.

AU - Beer, T. M.

AU - Beltran, H.

AU - Chinnaiyan, A. M.

AU - Daugaard, G.

AU - Davis, I. D.

AU - De Santis, M.

AU - Drake, C. G.

AU - Eeles, R. A.

AU - Fanti, S.

AU - Gleave, M. E.

AU - Heidenreich, A.

AU - Hussain, M.

AU - James, N. D.

AU - Lecouvet, F. E.

AU - Logothetis, C. J.

AU - Mastris, K.

AU - Nilsson, S.

AU - Oh, W. K.

AU - Olmos, D.

AU - Padhani, A. R.

AU - Parker, C.

AU - Rubin, M. A.

AU - Schalken, J. A.

AU - Scher, H. I.

AU - Sella, A.

AU - Shore, N. D.

AU - Small, E. J.

AU - Sternberg, C. N.

AU - Suzuki, H.

AU - Sweeney, C. J.

AU - Tannock, I. F.

AU - Tombal, B.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

AB - The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

KW - Advanced prostate cancer

KW - Castration-naïve prostate cancer

KW - Castration-resistant prostate cancer

KW - Consensus

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84940469697&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv257

DO - 10.1093/annonc/mdv257

M3 - Article

C2 - 26041764

AN - SCOPUS:84940469697

SN - 0923-7534

VL - 26

SP - 1589

EP - 1604

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -